Title: Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders
year: 2017
Journal: Eur Neuropsychopharmacol
Volume: 27
Issue: 11
Pages: 1153-1162
date: Nov
ISSN: 1873-7862 (Electronic);0924-977X (Linking)
Article Number: 28867303
Keywords: *Glucagon-like peptide-1;*Gray matter volume;*Liraglutide;*Mood disorders;*Neuroimaging;*Weight loss
Abstract: Cognitive deficits are a core feature across psychiatric disorders. Emerging evidence indicates that metabolic pathways are highly relevant for the substrates and phenomenology of the cognitive domain. Herein, we aimed to determine the effects of liraglutide, a GLP-1R agonist, on brain structural/volumetric parameters in adults with a mood disorder. This is the secondary analysis of a 4-week, pilot, proof-of-concept, open-label study. Participants (N=19) exhibiting impairments in executive function with either major depressive disorder (MDD) or bipolar disorder (BD) were recruited. Liraglutide 1.8mg/day was added as an adjunct to existing pharmacotherapy. Structural magnetic resonance imaging (MRI) scanning was obtained at baseline and endpoint. Results showed that at endpoint there was significant weight loss (mean: 3.15%; p<0.001). Changes in frontal and striatal volumes were significantly correlated with changes in body mass index (BMI), indicating the weight loss was associated with volume increase in most regions (e.g. r=-0.561, p=0.042 in the left superior frontal area). After adjusting for intracranial volume, age, gender, and BMI, we observed significant changes from baseline to endpoint in multiple regions (e.g. RR: 1.011, p=0.049 in the left rostral middle frontal area). Changes in regional volumes were associated with improvement in executive function (e.g. r=0.698, p=0.003 for the right superior frontal area). Adjunctive liraglutide results in clinically significant weight loss, with corresponding improvement in cognitive function; changes in cognitive function were partially moderated by changes in brain morphometry, underscoring the interrelationship between weight and brain structure/function.
Notes: Mansur, Rodrigo B;Zugman, Andre;Ahmed, Juhie;Cha, Danielle S;Subramaniapillai, Mehala;Lee, Yena;Lovshin, Julie;Lee, Jung G;Lee, Jae-Hon;Drobinin, Vladislav;Newport, Jason;Brietzke, Elisa;Reininghaus, Eva Z;Sim, Kang;Vinberg, Maj;Rasgon, Natalie;Hajek, Tomas;McIntyre, Roger S;eng;Research Support, Non-U.S. Gov't;Netherlands;2017/09/05 06:00;Eur Neuropsychopharmacol. 2017 Nov;27(11):1153-1162. doi: 10.1016/j.euroneuro.2017.08.433. Epub 2017 Sep 1.
URL: https://www.ncbi.nlm.nih.gov/pubmed/28867303
URI: https://open-access.imh.com.sg/handle/123456789/5146
Authors Address: Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada; Research Group in Molecular and Behavioral Neuroscience of Bipolar Disorder, Department of Psychiatry, Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil. Electronic address: rodrigomansur71@uol.com.br.;Interdiscipinary Laboratory of Clinical Neurosciences (LINC), Department of Psychiatry, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.;Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada.;Division of Endocrinology, Mount Sinai Hospital, University of Toronto, Toronto, Canada.;Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada; Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea.;Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada; Department of Psychiatry, Samsung Seoul Hospital, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea.;Department of Psychiatry, Dalhousie University, Halifax, Canada.;Research Group in Molecular and Behavioral Neuroscience of Bipolar Disorder, Department of Psychiatry, Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil.;Medical University of Graz, Department of Psychiatry, Graz, Austria.;Research Division, Institute of Mental Health, Singapore.;Psychiatric Center Copenhagen, University of Copenhagen, Copenhagen, Denmark.;Department of Psychiatry, Stanford University, Palo Alto, CA, United states.
Appears in Collections:2017

Files in This Item:
There are no files associated with this item.



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.